Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot Phase II Safety, Tolerability and Preliminary Efficacy of RSD1235-SR in Atrial Fibrillation
2005-004713-15Phase 2Completed
- Sponsor
- Correvio Pharma Corp.
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of vernakalant in Atrial fibrillation (AFib) and atrial flutter (AFL) (3 arms), sponsored by Correvio Pharma Corp. Primary endpoint: Safety assessments. Started Nov 2005; status: completed.
02
Drugs
vernakalant
03
Conditions
Atrial fibrillation (AFib)atrial flutter (AFL)
Beyond the preview
Go deeper on 2005-004713-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004713-15.